Baird Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces Price Target of $44
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has initiated coverage on PTC Therapeutics with an Outperform rating and set a price target of $44.
September 04, 2024 | 9:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Joel Beatty has initiated coverage on PTC Therapeutics with an Outperform rating and a price target of $44, suggesting potential upside.
The initiation of coverage with an Outperform rating and a specific price target of $44 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100